Replies to post #618293 on NorthWest Biotherapeutics Inc (NWBO)

[Reefrad]

Yeh that makes sense

[learningcurve2020]

Very positive press conference but let's stay real, folks.

"The data is a little tough to interpret in some ways"

"The data is a little bit messy but there's certainly signal there"

"The data is not as pristine as some would like".

"Almost doubled the proportion of patients driving over five years."

So, "Almost double" is not from 5 to 13%, as I've been saying, so the doc must believe 5 year is actually 7 or 8%.

Also doc say RI island likely has such a high rate of GBM because of the older population -60,70,80. We know older folks tend to pass faster. Keep in mind the average age of the L trial was 57.

Btw, This doc says the CEO told him the application for the FDA is in the works.

On the U:

DCVax-L® Press Conference at RI Hospital's Lifespan Cancer Institute. (Source: WRPI 12 News)

[biosectinvestor]

Yes, nGBM, rGBM and probably also some key categories of patients with certain biomarkers.

The one thing LC points out is yes, even when a doctor can say well over a 100% increase in survival for 5 year survivors they are typically trained to not overstate and tend to understate statistics like that… especially as this is not yet approved. Further, the company is letting the state talk and not actively crafting that language as it should be stated once this is approved. I hope and expect that they will get right on it, but honestly, there is not a single marketer among them, which is a pretty obvious tip off, I think, that they probably won’t be doing the marketing.

[Hspooner]

Let’s not forget, patients have been treated with DCVax-L in the UK since 2014 with the specials program, I’m sure all that patient data is part of the application process. Furthermore, that data may also provide the proverbial “Ace up my sleeve”, what better RWE than 100’s of real world patients receiving DCVax-L over the past 9 years.